The government provides temporary direct supply until the establishment of a supply system between hospitals and manufacturers
–
[연합뉴스 자료사진]
–
(Seoul = Yonhap News) Reporter Shin Jae-woo =’Recyronaju’, an antibody treatment for a novel coronavirus infection (Corona 19) developed in Korea, will be supplied to medical institutions from mid-month.
The Central Defense Response Headquarters (Bang Dae-bon) announced on the 6th that the government will directly purchase Rekkironaju (ingredient name Legdanvimab CT-P59) for a limited time and supply it to medical institutions from mid-February.
The Ministry of Food and Drug Safety (Ministry of Food and Drug Safety) officially licensed Rekirona, developed by Celltrion the day before, as an antibody treatment for Corona 19.
Daebon Bang explained that it takes time to prepare the product and the government directly supplies the treatment for a temporary period, and if a supply system is established between the medical institution and the pharmaceutical company, the inconvenience of use will be minimized.
Rekironaju is administered only to subjects approved by the Ministry of Food and Drug Safety.
The Ministry of Food and Drug Safety designates patients over 60 years of age with approval of Rekirona, mild patients with one or more chronic diseases of cardiovascular disease, chronic respiratory system disease, diabetes, and hypertension (underlying disease), and patients with pneumonia requiring oxygen therapy did.
In each medical institution, these patients can use Rekirona within 7 days of the onset of symptoms.
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2021/02/06 14:57 sent
–
